

**Antibiotics need to be looked upon as  
*lifesaving global public good* and  
not as a commercial commodity**



# A global failure

- Public policy
- Global governance
- Research prioritization
- Market system

# How did we end up here ?

- **Narrow framing as a medical/technical problem**
- **Semantical confusion**
- **Bacterial infections has not been given a disease face**
- **Lack of data on the burden of antibiotic resistance**
- **A global self-deception that new antibiotics will always be developed**

# The drug development pipeline for antibiotics



## No new drugs for:

- The last antibiotic for:
  - Typhoid fever
  - Shigella
  - Gonorrhoea
  - Urinary tract infections
  - Certain blood infections
  - .....
  - .....
- The oldest antibiotic effective due to
- The innovative drugs now

87 !



Muhimbili hospital, Dar es Salaam Tanzania

**The mortality rate from  
Gram-negative bloodstream  
infection in children (43,5 %)  
was more than double that  
of malaria.**

Blomberg et al. BMC Infect Dis. 2007



The problem of antibiotic resistance needs to be reframed as **“Access to effective treatment for bacterial infections”** and put into a **health systems perspective.**

**Sustainable, equitable  
and affordable**

**ACCESS TO EFFECTIVE  
TREATMENT FOR  
BACTERIAL INFECTIONS**

- **Needs driven R &D**
- **Controlled distribution**
- **Conservation policies**
- **Prevention of infections**

**Sustainable, equitable and  
affordable**

**ACCESS TO EFFECTIVE  
TREATMENT FOR  
BACTERIAL INFECTIONS**

- **Needs driven R &D**
- **Controlled distribution**
- **Conservation policies**
- **Prevention of infections**

**MEASURING THE  
PROBLEM**

- **Surveillance of AB  
resistance and use**
- **Burden of resistance**
- **Gap analysis**

**EDUCATION AND  
AWARENESS RAISING**

- **Policy makers**
- **Health care workers**
- **Civil society**



## **GOVERNANCE**

- **Global agreements**
- **Targets**
- **Accountability**

## **FINANCING**

- **Public sector**
- **Private sector**
- **Philantropists**

## **ACCESS TO EFFECTIVE TREATMENT FOR BACTERIAL INFECTIONS**

**Sustainable, equitable and  
affordable**

- **Needs driven R &D**
- **Controlled distribution**
- **Conservation policies**
- **Prevention of infections**

## **MEASURING THE PROBLEM**

- **Surveillance of AB  
resistance and use**
- **Burden of resistance**
- **Gap analysis**

## **EDUCATION AND AWAREESS RAISING**

- **Policy makers**
- **Health care workers**
- **Civil society**

## **COLLABORATION**

- **Within governments**
- **Between governments**
- **Between international organizations**
- **Between universities and science academies**
- **Between civil society organizations**
- **Between people**

## **COLLABORATION**

- **Within governments**
- **Between governments**
- **Between international organizations**
- **Between universities and science academies**
- **Between civil society organizations**
- **Between people**

## **ENTRY POINTS FOR ENGAGEMENT**

- **Post 2015 Development Agenda**
- **Universal Health Coverage**
- **Health systems strengthening**
- **Health security**
- **Ethics**
- **One health**

## **COLLABORATION**

- **Within governments**
- **Between governments**
- **Between international organizations**
- **Between universities and science academies**
- **Between civil society organizations**
- **Between people**

## **ENTRY POINTS FOR ENGAGEMENT**

- **Post 2015 Development Agenda**
- **Universal Health Coverage**
- **Health systems strengthening**
- **Health security**
- **Ethics**
- **One health**

## **POLITICAL VENUES FOR POLICY DEVELOPMENT**

- **UN**
- **World Economic Forum**
- **G8/G20**
- **OECD**
- **South Centre**
- **ICDRA**
- **.....**
- **.....**

